Nebenwirkungen · Evoltra
Evoltra 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-114446 · Präparat HOS-094089
Adverse reactions are listed by system organ class and frequency (very common (≥ 1/10); common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100; rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000)) in the table below. Adverse reactions reported during the post-marketing period are also included in the table under the frequency category “not known” (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-19T13:13:00Z · SHA-256 b6c4c8e2a08241633a344425bddf0c7c67b8e36cf88774f3228bedc236be1d69 · Passage 745a33c7f96c1e930bf857b734a9daabeb8a5edbeea2d2b7a908c19ce21fb64b · Zeichen 1343–1848 im Abschnitt